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We have previously shown that genetic disruption of Toxoplasma gondii calcium-dependent protein kinase 3 (TgCDPK3) affects
calcium ionophore-induced egress. We examined whether Plasmodium falciparum CDPK1 (PfCDPK1), the closest homolog of
TgCDPK3 in the malaria parasite P. falciparum, could complement a TgCDPK3mutant strain. PfCDPK1 is essential and plays
critical roles in merozoite development, motility, and secretion. We show that expression of PfCDPK1 in the TgCDPK3mutant
strain rescues the egress defect. This phenotypic complementation requires the localization of PfCDPK1 to the plasmamem-
brane and kinase activity. Interestingly, PfCDPK1-expressing Toxoplasma becomes more sensitive to egress inhibition by pur-
falcamine, a potent inhibitor of PfCDPK1 with low activity against TgCDPK3. Based on this result, we tested eight small mole-
cules previously determined to inhibit the kinase activity of recombinant PfCDPK1 for their abilities to inhibit ionophore-
induced egress in the PfCDPK1-expressing strain. While two of these chemicals did not inhibit egress, we found that six drugs
affected this process selectively in PfCDPK1-expressing Toxoplasma. Using mutant versions of PfCDPK1 and TgCDPK3, we
show that the selectivities of dasatinib and PLX-4720 are regulated by the gatekeeper residue in the ATP binding site. Impor-
tantly, we have confirmed that the three most potent inhibitors of egress in the PfCDPK1-expressing strain effectively kill P. fal-
ciparum. Thus, we have established and validated a recombinant strain of Toxoplasma that can be used as a surrogate for the
discovery and analysis of PfCDPK1-specific inhibitors that can be developed as antimalarials.
Toxoplasma gondii is a unicellular eukaryote classified in thephylumApicomplexa, which includes other notable pathogens
of humans and animals, including Plasmodium, Cryptosporidium,
Eimeria, andNeospora spp. (1). Themost infamous of the apicom-
plexan parasites is Plasmodium falciparum, which, as the causative
agent of malaria, is responsible for approximately 1.2 million
deaths every year, mostly among young children in tropical coun-
tries (2). Given the absence of human vaccines for any of the
apicomplexan parasites, palliative and curative drug treatments
are mainstays for reducing morbidity and mortality rates. How-
ever, resistance, toxicity, and lack of activity against certain stages
make available drugs of limited value; consequently, there is a dire
need for new antiapicomplexan drugs. Key to this endeavor is the
identification and in-depth study of proteins and processes
unique to and essential for the parasites. In this respect, the api-
complexan Toxoplasma gondii has emerged as a model organism
for study of the biology of apicomplexan parasites, with conve-
nient features such as simple inexpensive propagation in vitro and
the availability of sophisticated forward and reverse genetic tools
(3–5). Although T. gondii infection is asymptomatic in healthy
adults, it can cause fatal illness in individuals with immunocom-
promise or immunosuppression and in those infected congeni-
tally, and thus it is itself an important human pathogen (6).
In bothT. gondii and P. falciparum, calcium signaling is of spe-
cial interest since it controls essential events such as stage conver-
sion, motility, invasion, and egress and offers many targets for
selective treatment, due to the presence of unique calcium signal-
ing proteins (7). This is underscored by the presence of a family of
calcium-dependent protein kinases (CDPKs) in the respective ge-
nomes. Typically, CDPKs contain a kinase domain and four calm-
odulin-like EF-hand domains. Between these two features lies a
short peptide linker that, in the absence of calcium binding to the
EF-hand domains, interacts with the kinase domain and inhibits
its function (8, 9). While these unique kinases are abundant in
plants, ciliates, and parasites of the phylum Apicomplexa, they are
absent from animal cells (10). Consequently, CDPKs are being
aggressively pursued as attractive viable drug targets in both T.
gondii and P. falciparum (11–13). Of the seven CDPKs found in P.
falciparum (14), P. falciparum CDPK1 (PfCDPK1) is the best
characterized so far (13, 15–20). PfCDPK1 is localized to the pe-
riphery of the parasite (15, 18, 20) and has been shown to play key
signaling roles in motility (13), secretion (17), and development
(16) during the blood stages of the parasite. Additionally, in the
rodent malaria parasite Plasmodium berghei, CDPK1 is involved
in translational regulation during the insect stages (21). Attempts
to generate a gene knockout of PfCDPK1 have failed, suggesting
that its function is essential (13). Accordingly, analysis of
PfCDPK1 as a prospective drug target has mostly been based on
the use of purified recombinant protein or conditional genetic
disruption (18, 21).
Several groups, including ours, recently discovered that the
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ortholog of PfCDPK1 in T. gondii, T. gondii CDPK3 (TgCDPK3),
is not essential for parasite survival but plays an important role in
responding to induced exit from the host cell (22–24). In intracel-
lular T. gondii parasites, egress from the host cell can be induced
using theCa2 ionophoreA23187, so thatwithin 2min after treat-
ment nearly all intracellular parasites have actively escaped from
the parasitophorous vacuole and host cell (25). This process,
which is termed ionophore-induced egress (iiEgress), requires
parasite motility and secretion of various proteins, including a
perforin-like protein (T. gondii perforin-like protein 1 [TgPLP1])
that permeabilizes both the parasitophorous vacuolar membrane
and the host plasma membrane to facilitate escape (26). To eluci-
date the signaling events involved in iiEgress, we generated and
isolated chemically mutagenized parasites with significant delays
in iiEgress (27). Complete genome sequencing of one of these
mutants, MBE1.1, revealed that there was a single point mutation
in theTgcdpk3 open reading frame (ORF), resulting in a threonine
within the activation loop of the kinase domain being mutated to
isoleucine (T239I). Like PfCDPK1, TgCDPK3 is present at the
periphery of the parasite (22), where it presumably phosphory-
lates proteins that are part of either the machinery or regulatory
mechanisms for parasite motility. Importantly, the iiEgress
phenotype of MBE1.1 is complemented by incorporation of a
wild-type copy of TgCDPK3, confirming that this protein plays
an important role in the T. gondii lytic cycle (22). A role for
TgCDPK3 in iiEgress was also reported by others, who used either
a Tgcdpk3-knockout strain (24) or a chemical genetic approach
(23). To date, however, the mechanistic reasons for the delay in
iiEgress resulting from lack of TgCDPK3 function have not been
elucidated.
In this study,we show that PfCDPK1 complements the absence
of TgCDPK3 in T. gondii during iiEgress, establishing a system
that can be easily manipulated to explore the functions of
PfCDPK1 in a cellular context.Moreover, we show that our trans-
genic parasite expressing PfCDPK1 can serve as a surrogate to
identify specific inhibitors that have potent activity against P. fal-
ciparum parasites.
MATERIALS AND METHODS
Parasite cultures.Toxoplasma gondii tachyzoites weremaintained by pas-
sage through human foreskin fibroblasts (HFFs) in a humidified incuba-
tor at 37°C with 5% CO2. Normal growth medium consisted of Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 2mML-glutamine, and 50g/ml of penicillin-strep-
tomycin. Purification of parasites was performed as described previously
(28).
Chemicals. Lestaurtinib and sunitinib were purchased from Tocris
Biosciences. Nilotinib and PLX-4720 were purchased from Selleckchem.
Dasatinib and sorafenib were purchased from Santa Cruz Biotechnology.
Staurosporine was obtained from Sigma. Pazopanib was purchased from
Synthonix. Drugs were resuspended in dimethyl sulfoxide (DMSO) as 10
mM stock solutions.
Plasmid constructs. Primers used to generate plasmid constructs,
as described in this section, are listed in Table S1 in the supplemental
material. To express PfCDPK1 and TgCDPK3 under the control of the
TgCDPK3 promoter, we replaced the Sag1 promoter in the previously
described pTgCDPK3 complementation construct (22) by the 4,000
bases immediately upstream of the TgCDPK3 start codon by using the
HindIII and NcoI sites flanking the promoter, generating vector
pTgcdpk3CDPK3-HA. A codon-optimized copy of the PfCDPK1 open
reading frame (ORF) with a hemagglutinin (HA) tag at the C terminus
was commercially synthesized (GenScript) (see Fig. S1 in the supple-
mental material), amplified by PCR, and directionally cloned down-
stream of the Tgcdpk3 promoter in the vector pTgcdpk3CDPK3-HA,
using the NcoI and PacI sites, to generate pTgcdpk3PfCDPK1-
HA. The localization mutant pTgcdpk3PfCDPK1(GCAA)-HA, the kinase
mutant pTgcdpk3PfCDPK1(T231I)-HA, and the gatekeeper mutants
pTgcdpk3PfCDPK1(T145M)-HA and pTgcdpk3TgCDPK3(M153T)-HA were
made using a Quick-change XL site-directed mutagenesis kit (Stratagene), ac-
cording to manufacturer’s instructions, with either pTgcdpk3PfCDPK1-HA or
pTgcdpk3CDPK3-HAastheparentplasmid.Allresultingconstructswereverified
by restrictiondigestion and sequencing.
Stable transfection. Plasmid constructs were linearized with the re-
striction enzyme KpnI, purified, and electroporated into T. gondii
tachyzoites according to established protocols (29). Parasite populations
with stable integration of the transfected construct were selected by cul-
turing in the presence of 50 g/ml mycophenolic acid (MPA) and 50
g/ml xanthine and were cloned by limiting dilution.
Immunoblotting. Parasite lysates were heated at 100°C for 5 min in
SDS-PAGE sample buffer with 2% 2-mercaptoethanol and were resolved
on a 4 to 20% gradient gel (Bio-Rad, Hercules, CA). Proteins from the gel
were transferred to nylon membranes by using a semidry transfer appa-
ratus (Bio-Rad, Hercules, CA) at 12 V for 30 min. After blocking with 5%
(wt/vol) skim milk powder in Tris-buffered saline (TBS), membranes
were treated with the primary antibody, rabbit anti-HA antibody (Cell
Signaling Technology), for 1 h. Membranes were then washed and incu-
bated with secondary antibodies, i.e., goat-anti-rabbit IgG conjugated to
horseradish peroxidase (Sigma). After washing, membranes were treated
with SuperSignal West Pico chemiluminescent substrate (Pierce Chemi-
cal) and imaged using a FluorChem E system (ProteinSimple).
Immunofluorescence microscopy. Immunofluorescence staining of
intracellular parasites was performed according to previously described pro-
cedures (30).Briefly, freshly lysedparasiteswereaddedontoconfluentmono-
layers of HFFs on coverslips in a 24-well tissue culture plate. Sixteen hours
postinfection, coverslips were washed three times with phosphate-buffered
saline (PBS) and fixed with 4% formaldehyde for 20 min. Fixed cells were
permeabilizedwith0.1%TritonX-100 for10minandblockedwith10%FBS.
After 30minofblocking,primaryantibodiesdiluted inPBSwere added to the
coverslips. The primary antibodies used were rabbit anti-HA (Cell Signaling
Technology) and mouse anti-IMC1. After 1 h, coverslips were washed three
times with PBS, and secondary Alexa fluorophore-conjugated antibodies
were added. Secondary antibodies used included Alexa Fluor 594- or Alexa
Fluor 488-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (Molecu-
lar Probes). After 1 h, coverslips werewashed three times andmounted using
Vectashield DAPI (4=,6-diamidino-2-phenylindole) (Vector Laboratories
Inc.). Slides were viewed using a Nikon Eclipse E100080i microscope, and
digital images were captured with a Hamamatsu C4742-95 charge-coupled
device camera using NIS-Elements software.
Ionophore-induced egress assay. The efficiency of egress after cal-
cium ionophore treatment was determined using established protocols
(22). Briefly, freshly harvested parasites were added to a 24-well plate
containing confluent HFFs at a multiplicity of infection (MOI) of 1 and
were incubated at 37°C for 30 h. To induce egress, intracellular parasites
were washed with warm PBS, incubated at 37°C for 2 min in Hanks’
balanced salt solution (HBSS) containing 1 M calcium ionophore
A23187, and fixed with 100% methanol. To visualize intact and lysed
vacuoles, the cultures were stained using Diff-Quik (Dade-Behring) ac-
cording to the manufacturer’s instructions. Percent egress was deter-
mined by dividing the number of lysed vacuoles by the total number of
vacuoles for a sample. To test the effects of various drugs on parasite
egress, intracellular parasites were pretreated for 15 min at 37°C with the
chemical being investigated in normal growth medium and were washed
once with PBS before the addition of HBSS with 1 M A23187. Cultures
were fixed, stained, and analyzed as described above.
Plasmodium falciparum culture anddrug assays.Plasmodium falcip-
arum parasites of the HB3 strain were grown in human red blood cells
using RPMI 1640 medium supplemented with 0.5% Albumax I (Invitro-
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gen, Carlsbad, CA), 0.25% sodiumbicarbonate, and 0.01mg/ml gentami-
cin, under an atmosphere of 90% nitrogen, 5% oxygen, and 5% carbon
dioxide. Parasite synchrony was maintained by treatment with 5% sorbi-
tol solution. The in vitro antiparasitic effects of the various drugs were
assessed by the [3H]hypoxanthine (PerkinElmer Life Sciences, Boston,
MA) incorporation assay, according to previously described protocols
(31). Percent inhibition of growth was plotted against log drug concen-
tration to generate dose-response curves. The half-maximal inhibitory
response, defined as the drug concentration at which growth was inhib-
ited by 50% (IC50), was estimated by curve-fitting the response data with
a variable-slope sigmoidal function (Prism 4.0c; GraphPad Software, San
Diego, CA).
Molecular modeling.Homology models of TgCDPK3 and PfCDPK1
in the Ca2-bound activated state were created with Modeler (32), using
the PbCDPK3 structure (PDB accession no. 3Q5I) as a template. For
superposed models, the structure of Abl (PDB accession no. 2GQG) with
dasatinib or B-Raf (PDB accession no. 3C4C) with PLX-4720 was super-
posed in PyMOL (Schrodinger), and the structural alignment was verified
manually. In addition, the drugs were docked to the models of TgCDPK3
and PfCDPK1 using AutoDock Vina (33), with the search space centered
on the active site and sized 20 Å in all dimensions.
RESULTS
Plasmodium falciparum PfCDPK1 rescues the egress pheno-
type of the Toxoplasma gondii Tgcdpk3 mutant. To determine
whether function is conserved across species for TgCDPK3 ho-
mologs, we tested whether PfCDPK1 from P. falciparum could
complement the delayed egress phenotype of the T. gondii
Tgcdpk3-mutant strainMBE1.1 (22, 27). To achieve this objective,
a codon-optimized copy of PfCDPK1 (see Fig. S1 in the supple-
mental material) with an HA tag at the C terminus (PfCDPK1-
HA) was transfected into MBE1.1 parasites, and a clone stably
expressing PfCDPK1 (MBE1.1PfCDPK1) was established by
limiting dilution. As a control, we also generated a MBE1.1 line
complemented with the wild-type version of TgCDPK3 carrying
an HA tag at its C terminus (MBE1.1TgCDPK3). The expres-
sion of PfCDPK1 and TgCDPK3 in the complemented parasites
was confirmed byWestern blotting using antibodies against the HA
tag (Fig. 1A). PfCDPK1 migrates slightly faster than TgCDPK3,
which is consistent with their expected sizes. To determine whether
PfCDPK1 is correctly localized in theMBE1.1PfCDPK1clone, par-
asiteswereexaminedby immunofluorescenceassays (IFAs). Just as in
the case of the endogenous protein (22) and the exogenously ex-
pressed TgCDPK3 (Fig. 1B), PfCDPK1 localizes to the periphery of
the parasite when expressed in T. gondii (Fig. 1B).
Next, to determine whether PfCDPK1 can complement
TgCDPK3 function in iiEgress, we exposed MBE1.1PfCDPK1
parasites to the Ca2 ionophore A23187. After 2 min of incuba-
tion with 1 MA23187, 99.6% 0.7% of MBE1.1-mutant para-
sites remained inside the cells, whereas nearly all of the MBE1.1
parasites expressing either PfCDPK1 (96.1% 3%) or TgCDPK3
(96.4%  1.9%) were outside their host cells (Fig. 1C). These
results show that PfCDPK1 successfully complements the iiEgress
defect of Tgcdpk3-mutant T. gondii tachyzoites.
FIG 1 PfCDPK1 complements the iiEgress phenotype of theT. gondii Tgcdpk3mutant strainMBE1.1. (A)Western blot analysis ofMBE1.1 clones complementedwith
either TgCDPK3-HA or PfCDPK1-HA was performed with anti-HA antibody. (B) Localization of PfCDPK1-HA and TgCDPK3-HA in intracellular parasites was
examined by IFA using anti-HA antibody. IMC1 antibody was used as a control to stain the inner membrane complex, which lies directly underneath the plasma
membrane. Scale bar, 2 m. (C) Intracellular parasites of strains MBE1.1 and MBE1.1 complemented with PfCDPK1-HA were analyzed for egress efficiency by
treatmentwith theCa2 ionophoreA23187 for 2min at 37°C. Percent egress represents thenumber of lysed vacuoles dividedby the total number of vacuoles (lysedplus
intact) (n 3 independent experiments). Error bars, standard error of the mean (SEM).MW,molecular weight (in thousands). , P 0.05, Student’s t test.
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Complementation by PfCDPK1 relies on its localization to
plasma membranes and its kinase activity. We next wanted to
determine whether the complementation of the iiEgress phenotype
by PfCDPK1 was due to its kinase activity at the parasite periphery.
Previous studies have shown that TgCDPK3 localization to the pe-
riphery of the parasite is mediated by the second and third residues
(glycine and cysteine, respectively), which are both predicted to be
lipidated, and thatmembrane localization is essential for its function
(22–24). Both of these residues are conserved in PfCDPK1. To test
whether these residues contribute to the trafficking of PfCDPK1 to
plasmamembranes in T. gondii, we transformedMBE1.1 parasites
with a version of PfCDPK1 in which G2 and C3 are each mu-
tated to alanine, i.e., PfCDPK1(G2AC3A). The expression of
PfCDPK1(G2AC3A)was confirmed by immunoblotting (Fig. 2A)
and, when examined by IFA, PfCDPK1 showed a punctate distri-
bution throughout the parasite, suggesting cytoplasmic localiza-
tion (Fig. 2B). To test whether localization of PfCDPK1 to the
membrane was needed for its ability to complement the iiEgress
phenotype of the MBE1.1 mutant, we exposed intracellular
MBE1.1PfCDPK1(G2AC3A) parasites to 1 M A23187 for 2
min. While MBE1.1PfCDPK1 parasites efficiently undergo
egress at this time point, we observed only 1%  0.7% egress
for the parasites complemented with the localization mutant
(Fig. 2C).
To testwhether the kinase activity of PfCDPK1 is important for
its ability to function in the context of T. gondii iiEgress, we de-
signed a plasmid vector in which T231 is mutated to isoleucine
and we transfected the vector intoMBE1.1 parasites. Earlier stud-
ies examining the kinase activity of recombinant PfCDPK1
showed that T231 is within the activation loop of PfCDPK1 and is
essential for its kinase activity (34). Expression of the kinase mu-
tant PfCDPK1(T231I) inMBE1.1was confirmed byWestern blot-
ting (Fig. 2D) and,when examined by IFA, themutant proteinwas
localized to the parasite periphery, as expected (Fig. 2E). The ki-
nase-mutant parasites were then analyzed for egress efficiency us-
ing A23187. MBE1.1PfCDPK1(T231I) parasites failed to un-
dergo egress within 2 min after ionophore treatment, suggesting
that loss of kinase activity abolishes the ability of PfCDPK1 to
complement a lack of TgCDPK3 (Fig. 2F).
PfCDPK1-expressing T. gondii can be used as a tool to iden-
tify antimalarial compounds. By generating the transgenic strain
MBE1.1PfCDPK1, we have created a T. gondii strain that de-
pends on PfCDPK1 for efficient iiEgress, a process that can be
easily monitored and is amenable to inhibition by small mole-
cules. Consequently, we reasoned that the transgenic parasites
might provide a good system to screen and to identify novel
PfCDPK1 inhibitors. To validate this idea, we tested whether
known inhibitors of PfCDPK1 could disrupt iiEgress in the
MBE1.1PfCDPK1 parasites. Purfalcamine is a potent inhibitor
of recombinant PfCDPK1 (IC50, 230 nM) that was identified
FIG 2 Localization and kinase activity of PfCDPK1 are important for complementation of the iiEgress phenotype. MBE1.1 parasites were complemented with
either wild-type PfCDPK1, PfCDPK1(G2AC3A), which is mutated at the amino acids involved in localization (A to C), or PfCDPK1(T231I), which is mutated
at an amino acid required for kinase activity (D to F). (A and D) Western blot analyses to determine the expression of PfCDPK1 and mutant versions were
performed with anti-HA antibody. (B and E) Localization of PfCDPK1(G2AC3A) (B) and PfCDPK1(T231I) (E) in MBE1.1 was examined in intracellular
parasites by IFA using anti-HA antibody. (C and F) Intracellular Tgcdpk3-mutant parasites (MBE1.1) complemented with the localization mutant
PfCDPK1(G2AC3A) (C), the kinase mutant PfCDPK1 (T231I) (F), or wild-type PfCDPK1 (C and F) were analyzed for egress efficiency by treatment with the
Ca2 ionophore A23187 for 2 min. Percent egress represents the number of lysed vacuoles divided by the total number of vacuoles (lysed plus intact) (n  3
independent experiments). Scale bar, 2 m. Error bars, SEM. MW, molecular weight (in thousands). , P 0.05, Student’s t test.
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through an in vitro chemical screen (13). We previously showed
that purfalcamine can also inhibit the kinase activity of recombi-
nant TgCDPK3 and can cause a delay in T. gondii iiEgress (22),
albeit at much higher concentrations (25 to 50 M) than those
needed to affect PfCDPK1. Consequently, we hypothesized that
MBE1.1PfCDPK1 parasites would be more susceptible to pur-
falcamine inhibition than MBE1.1TgCDPK3 parasites; to test
this possibility, intracellular parasites of either strain were pre-
treated with various concentrations of purfalcamine for 15
min, followed by ionophore treatment. As expected, neither 2.5
nor 5 M purfalcamine affected iiEgress of the TgCDPK3-ex-
pressing parasites (Fig. 3). On the other hand, pretreatment of
MBE1.1PfCDPK1 parasites with either 2.5 or 5 M purfal-
camine completely blocked iiEgress (Fig. 3). Thus, expression of
the P. falciparum ortholog makes T. gondii more sensitive to in-
hibitors that affect the kinase activity of recombinant PfCDPK1.
A previous study that examined the effects of 72 kinase inhib-
itors on 442 kinases showed that 20 of those compounds inhibited
recombinant PfCDPK1 kinase activity in vitro at concentrations of
less than 5 M (35). We chose eight compounds (lestaurtinib,
sorafenib, pazopanib, dasatinib, nilotinib, sunitinib, staurospor-
ine, and PLX-4720) (for structures, see Fig. S2 in the supplemental
material) that showed the lowestKd values, ranging from 0.25 nM
to 1,300 nM (Table 1), for testing of their effects on iiEgress. Based
on our previous experience with inhibitors of iiEgress (22), we
decided to perform our initial assays using a drug concentration
approximately 10-fold higher than the Kd of the weakest in
vitro PfCDPK1 inhibitor being tested. Accordingly, intracellular
MBE1.1 parasites complemented with either TgCDPK3 or
PfCDPK1 were treated with the inhibitors at 10 M for 15 min
prior to the induction of iiEgresswith 1MA23187 for 2min. The
results showed that two drugs, staurosporine and lestaurtinib,
completely blocked egress in both strains at the concentration
tested, while two other drugs, pazopanib and nilotinib, did not
affect iiEgress in either strain (Table 1). Importantly, we found
that four drugs, PLX-4720, dasatinib, sunitinib, and sorafenib,
inhibited iiEgress of only MBE1.1PfCDPK1 parasites (Table 1).
Since T. gondii becomes sensitive to these four kinase inhibitors
only when it is dependent on PfCDPK1 for efficient iiEgress, our
results show that, within the context of T. gondii, these drugs are
specific for PfCDPK1.
To better define the activities of the various kinase inhibitors,
IC50s were assessed by testing the effect of each drug on iiEgress
using a 2-fold dilution series. For lestaurtinib and staurosporine,
both of which inhibited iiEgress in both strains, we detected lower
IC50s in the PfCDPK1-expressing parasites (Table 2; also see Fig.
S3 and S4 in the supplemental material). For lestaurtinib, the IC50
for the PfCDPK1-expressing line was 0.16 M and that for the
TgCDPK3-expressing parasites was 0.46 M. Staurosporine was
slightly less potent, with IC50 values of 0.32M for the PfCDPK1-
expressing parasites and 1.15 M for the TgCDPK3-expressing
ones (Table 2; also see Fig. S3 in the supplemental material). For
the four drugs that inhibited iiEgress in only the PfCDPK1-ex-
pressing parasites at 10M, the IC50s were 1.36Mfor PLX-4720,
1.17 M for dasatinib, 6.05 M for sunitinib, and 6.66 M for
sorafenib (Table 2; also see Fig. S4 in the supplemental material).
Thus, using our novel transgenic T. gondii strain, we have deter-
mined that six drugs, namely, PLX-4720, dasatinib, sunitinib,
sorafenib, lestaurtinib, and staurosporine, can inhibit the func-
tion of PfCDPK1 within a cellular context.
The gatekeeper residue is a major determinant of dasatinib
and PLX-4720 sensitivities. The kinase inhibitors we have tested
so far are thought to affect kinase activity by binding to the ATP
binding site. Although TgCDPK3 shares significant identity with
PfCDPK1 within this region (see Fig. S5 in the supplemental ma-
terial), there must be some amino acid variation that accounts for
FIG 3 Tgcdpk3 mutants expressing PfCDPK1 are more sensitive to egress
inhibition by purfalcamine. Intracellular parasites of the Tgcdpk3 mutant
(MBE1.1) and Tgcdpk3 mutants complemented with either wild-type PfCDPK1
(MBE1.1PfCDPK1) or wild-type TgCDPK3 (MBE1.1TgCDPK3) were
treated with purfalcamine for 15 min and exposed to A23187 for 2 min. Per-
cent egress represents the number of lysed vacuoles divided by the total
number of vacuoles (lysed plus intact) (n 3 independent experiments). Error
bars, SEM. , P 0.05, Student’s t test.
TABLE 1 Effects of kinase inhibitors on ionophore-induced egress
efficiency of Tgcdpk3mutants complemented with TgCDPK3 or
PfCDPK1
Compound
Kd (nM) for
recombinant
PfCDPK1
(35)
Inhibition ofa:
MBE1.1TgCDPK3 MBE1.1PfCDPK1
Staurosporine 0.25 Yes Yes
CEP-701
(lestaurtinib)
5.6 Yes Yes
PLX-4720 1.7 No Yes
Dasatinib 640 No Yes
Sunitinib 1,300 No Yes
Sorafenib 220 No Yes
Nilotinib 790 No No
Pazopanib 370 No No
a Intracellular parasites were treated with various drugs at 10 M concentrations for 15
min and were exposed to A23187 for 2 min at 37°C. Yes, 100% inhibition; no,15%
inhibition.
TABLE 2 IC50 values for iiEgress inhibitors
Drug
IC50 (M) for
a:
MBE1.1PfCDPK1 MBE1.1TgCDPK3
CEP-701 (lestaurtinib) 0.16 0.46
Staurosporine 0.32 1.15
Dasatinib 1.17
PLX-4720 1.36
Sunitinib 6.05
Sorafenib 6.66
a IC50 values were calculated for the drugs that inhibited iiEgress in Tgcdpk3mutants
(MBE1.1) stably expressing either PfCDPK1 or TgCDPK3 and for those that inhibited
egress of only MBE1.1 complemented with PfCDPK1. The assay used consisted of
treating intracellular parasites with 2-fold dilutions of the inhibitor for 15 min and then
exposing the cultures to 1 MA23187 for 2 min to induce egress. The values shown are
the average of 3 independent experiments.
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the differences between the two proteins in sensitivity to the in-
hibitors tested. To determine the residues likely to affect the spec-
ificity of each drug, we modeled the binding of dasatinib, PLX-
4720, and lestaurtinib to the structures of TgCDPK3 and
PfCDPK1 (Fig. 4A). Modeling of the kinases with staurosporine
was not done, given the great structural similarities between les-
taurtinib and staurosporine. For our in silico modeling experi-
ments, we first used the known crystal structures of dasatinib
bound to Abl (PDB accession no. 2GQG) (36) and PLX-4720
bound to B-Raf (PDB accession no. 3C4C) (37) to create an initial
model of the drugs bound to either TgCDPK3 or PfCDPK1. In
both cases, the drugs would be expected to bind well to PfCDPK1
but not TgCDPK3, due to clashes at the TgCDPK3 gatekeeper
residue. While TgCDPK3 has a typical bulky gatekeeper (M153),
PfCDPK1 has a smaller threonine at the equivalent position
(T145). Consistent with this model, both Abl and B-Raf have Thr
gatekeepers. We also created a model of lestaurtinib bound to the
two CDPKs using AutoDock Vina (33). This model predicts sim-
ilar binding modes for lestaurtinib binding to the two proteins,
not determined by the gatekeeper residue (Fig. 4A).
To determine whether the selectivities of the inhibitors for
PfCDPK1 over TgCDPK3 are altered by mutation of the gatekeeper
residues, as would be predicted for dasatinib and PLX-4720, we
transfected MBE1.1 parasites with either PfCDPK1 with its gate-
keeper residue mutated to methionine [PfCDPK1(T145M)] or
TgCDPK3 with its gatekeeper residue mutated to threonine
[TgCDPK3(M153T)]. Expression of these mutant constructs in
MBE1.1 parasites was confirmed by immunoblotting (see Fig. S6A
and C in the supplemental material), and IFAs showed that both
mutant proteins localize to the parasite periphery (see Fig. S6B andD
in the supplemental material). The sensitivities of the parasite lines
MBE1.1PfCDPK1(T145M) and MBE1.1TgCDPK3(M153T) to
PLX-4720, lestaurtinib, dasatinib, and staurosporine were tested by
preincubating the lines with these inhibitors for 15 min prior to the
induction of egress for 2 min. For these assays, we used the minimal
concentrationof each inhibitor forwhich 100% inhibitionof iiEgress
was observed (i.e., 4MPLX-4720, 2Mdasatinib, 0.5Mlestaur-
tinib, and 1 M staurosporine). Mutating the gatekeeper residue of
TgCDPK3or PfCDPK1did not affect the sensitivity to either lestaur-
tinib or staurosporine (Fig. 4B and C). These results suggest that, as
suggested by our structural models, the difference in the activities of
lestaurtinib and staurosporine against TgCDPK3 and PfCDPK1 is
influenced by sequence or structural differences other than, or in
addition to, the gatekeeper residue.
PLX-4720 and dasatinib completely inhibited iiEgress in the
MBE1.1PfCDPK1parasites at 4 and 2M, respectively (Fig. 4C)
but had nearly no effect on MBE1.1TgCDPK3 parasites at the
same concentrations (Fig. 4B). Consistent with the interaction
models, we found that the gatekeeper residue was a strong deter-
minant of the specificity of PLX-4720 and dasatinib for PfCDPK1.
The specificity of both of these inhibitors was reversed in the re-
spective gatekeeper mutants; MBE1.1PfCDPK1(T145M) be-
came resistant to inhibition and MBE1.1TgCDPK3(M153T)
became sensitive (Fig. 4B and C). These results show that the re-
spective gatekeeper residues in these orthologs are greatly respon-
sible for the differences in sensitivity to PLX-4720 and dasatinib
FIG4 The gatekeeper residue regulates the sensitivity of PfCDPK1 andTgCDPK3 to dasatinib and PLX-4720. (A)Molecularmodels of dasatinib, PLX-4720, and
lestaurtinib bound to TgCDPK3 (blue) and PfCDPK1 (orange) were prepared. Drugs and gatekeeper residues are shown as sticks. The bulky M153 gatekeeper
in TgCDPK3 is shown in space-filling gray to highlight clashes with dasatinib and PLX-4720. (B and C) Intracellular Tgcdpk3-mutant parasites (MBE1.1)
complemented with the gatekeeper mutants TgCDPK3(M153T) (B) and PfCDPK1(T145M) (C) were treated for 15 min with the inhibitors indicated and were
exposed to A23187 for 2 min at 37°C. Percent egress represents the number of lysed vacuoles divided by the total number of vacuoles (lysed plus intact) (n 3
independent experiments). Error bars, SEM. *, P 0.05, Student’s t test.
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we detect and thesemolecules inhibit PfCDPK1 function by inter-
acting with the ATP binding site. Furthermore, these results dem-
onstrate how the genetic tractability of T. gondii can be exploited
to study the mode of action of PfCDPK1 inhibitors.
Activation of PKG overcomes egress block of PfCDPK1 in-
hibitors.Given the fact that, at certain concentrations, PLX-4720,
lestaurtinib, dasatinib, and staurosporine inhibit iiEgress only
when T. gondii depends on the P. falciparum ortholog for this
function, it is unlikely that the inhibition is due to an off-target
effect. Nonetheless, it is plausible that these kinase inhibitors can
affect other kinases in T. gondii in other functional contexts. An-
other kinase that seems to play roles parallel to those of CDPKs in
both T. gondii and P. falciparum is protein kinase G (PKG). Inter-
estingly, PKG appears to be involved in the regulation of egress in
both of these parasite species (23, 38). It has been shown that
treatment of intracellular parasites with zaprinast (a cGMP-spe-
cific phosphodiesterase [PDE] inhibitor), which presumably leads
to increased cGMP levels and prolonged PKG function, can in-
duce egress in both T. gondii (23) and P. falciparum (38). Interest-
ingly, in T. gondii, zaprinast treatment can overcome the iiEgress
delay observed in parasites in which the function of TgCDPK3 has
been inhibited (23), indicating that there are at least two parallel
signaling pathways regulating egress. We took advantage of this
observation to test whether, under the conditions of the iiEgress
test, PLX-4720, lestaurtinib, dasatinib, or staurosporine could in-
hibit PKG activity. The general approach was to pretreat parasites
with the various inhibitors before inducing egress with zaprinast.
If the inhibitors had an effect on PKG in addition to their effects
on PfCDPK1, then zaprinast would fail to induce egress in their
presence. As a first step, we tested the effects of different concen-
trations of zaprinast to induce egress in our intracellular Tgcdpk3
mutants. The results showed that zaprinast was able to induce
MBE1.1 parasites to undergo egress within 4 min after treatment
at both 0.25 and 0.5 mM (Fig. 5A). We saw the same induction of
egress by 0.25 and 0.5 mM zaprinast in the PfCDPK1-expressing
strain (Fig. 5B). Next, to examine whether PLX-4720, lestaurtinib,
dasatinib, or staurosporine had effects on PKG activation, intra-
cellularMBE1.1PfCDPK1parasites were treated for 15minwith
the inhibitors at concentrations determined to affect PfCDPK1,
followed by the addition of zaprinast. The results showed that
zaprinast was able to induce egress in PLX-4720-, lestaurtinib-,
and dasatinib-treated parasites at levels equal to those of untreated
parasites (Fig. 5B). However, for parasites pretreated with stauro-
sporine, the level of egress induction did not reach 100%, with
respect to the untreated parasites, even at 0.5 mM zaprinast (Fig.
5B). These results show that PLX-4720, lestaurtinib, and dasatinib
do not affect PKG and exhibit specificity for PfCDPK1 within the
context of T. gondii egress. Furthermore, we have determined that
staurosporine might be affecting either PKG or other proteins
downstream of the PKG-dependent egress pathway, albeit less ef-
ficiently than its inhibition of PfCDPK1.
PfCDPK1-inhibiting drugs affect malaria parasite growth.
Our studies have identified four small molecules that specifically
and strongly inhibit the function of PfCDPK1 within the cellular
context of T. gondii. To confirm that our use of T. gondii as a
surrogate to find inhibitors of PfCDPK1 is a valid approach to find
antimalarial compounds, we tested whether the PfCDPK1 inhib-
itors we identified had activity against P. falciparum. While PLX-
4720, lestaurtinib, dasatinib, and staurosporine had been shown
previously to inhibit the kinase activity of recombinant PfCDPK1
in vitro (35), only staurosporine was tested against Plasmodium
parasites and shown to inhibit parasite growth in culture (39).
Consequently, we tested the effects of PLX-4720, lestaurtinib, and
dasatinib in the inhibition of erythrocytic growth of P. falciparum
strainHB3. For this purpose, P. falciparum growthwasmonitored
using a standard [3H]hypoxanthine incorporation assay, which is
based on the use of hypoxanthine as a major source of purine
nucleotide biosynthesis by malaria parasites (40). Hence, incor-
poration of tritium-labeled hypoxanthine into parasite DNA di-
rectly reflects parasite growth in erythrocytes. All three drugs in-
hibited P. falciparum parasite growth; lestaurtinib was the most
potent drug, with an IC50 of 75 nM (Fig. 6). The IC50 for dasatinib
was 2.9 M, and that for PLX-4720 was 10.6 M. These results
correlate well with what we observed for inhibition of iiEgress in
T. gondii; in that context, lestaurtinib was the most powerful in-
hibitor, with an IC50 of 160 nM, followed by dasatinib (iiEgress
IC50 of 1.17 M) and PLX-4720 (iiEgress IC50 of 1.36 M).
DISCUSSION
The development of a variety of molecular genetic tools and a
simple cell culture system has led some to propose Toxoplasma
gondii as amodel to study apicomplexan parasites, including Plas-
modium spp. (41). In this study, we show that the delayed egress
phenotype observed in T. gondii parasites lacking a functional
TgCDPK3 can be rescued by complementation with the P. falcip-
arum ortholog PfCDPK1. Importantly, we also demonstrate that
TgCDPK3 mutants of T. gondii expressing PfCDPK1 can be used
FIG 5 The inducer of PKG signaling zaprinast rescues egress inhibition of
kinase inhibitors. (A) Intracellular TgCDPK3 mutants (MBE1.1) were ex-
posed to various concentrations of Zaprinast for 4 min at 37°C. Percent egress
represents the number of lysed vacuoles divided by the total number of vacu-
oles (lysed plus intact). (B) Intracellular Tgcdpk3-mutant parasites comple-
mented with PfCDPK1 (MBE1.1PfCDPK1) were treated with the indicated
inhibitors for 15min and exposed to zaprinast at 0.0, 0.25, or 0.5mM for 4min
at 37°C. Percent egress represents the number of lysed vacuoles divided by the
total number of vacuoles (lysed plus intact) (n 3 independent experiments).
Error bars, SEM. , P 0.05, Student’s t test.
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as a surrogate system to screen and to identify novel inhibitors.
Thus, our study represents a concrete example of how T. gondii
can be exploited to study the function and drug susceptibility of
Plasmodium proteins.
Apicomplexan pathogens share many basic features, such as
specialized secretory organelles, motility components, and lytic
modes of propagation, as well as conserved apicomplexan-specific
genes. These conserved proteins have homology not only at the
sequence level but also at the localization and in many cases func-
tional levels. Nonetheless, given the significant differences among
apicomplexans in terms of host cell range, transmission modes,
and life cycles, it is suspected that some protein homologs have
evolved distinct functions within their particular parasites. Con-
sequently, examples of cross-genus complementation within the
Apicomplexa are limited. These examples include complementa-
tion of a T. gondii GAP45 mutant with the Plasmodium homolog
(42) and of a T. gondii strain lacking IMP dehydrogenase with the
Cryptosporidium protein (43). In such cases, when function is
across species, T. gondii can serve as a model to study structure-
function aspects of proteins from parasites for which tissue cul-
ture is not optimal, e.g., P. falciparum, or for which genetic tools
are not available, such as Cryptosporidium. While TgCDPK3 and
PfCDPK1 share 57% identity and 71% similar residues, it was not
evident a priori whether function would be conserved. PfCDPK1
has been implicated in microneme secretion and parasite inva-
sion, and complete disruption of TgCDPK3 does not affect these
processes. Furthermore, the disparity in sensitivities to purfal-
camine (22) suggests structural differences between these two
proteins, which could affect substrate specificity. We have shown
that PfCDPK1 can complement the lack of TgCDPK3 and, in do-
ing so, we have generated a novel tool to identify and to charac-
terize inhibitors of this essential Plasmodium kinase.
While PfCDPK1 can replace TgCDPK3 in T. gondii in the con-
text of iiEgress, as mentioned above, it is unlikely that these two
orthologs have identical substrates and functions within their re-
spective parasites. In vitro studies using recombinant proteins
have shown that PfCDPK1 can phosphorylate myosin light chain
and glideosome-associated protein 45, two important compo-
nents of the parasite motor complex (18, 44, 45). Although some
of the sites phosphorylated in vitro by PfCDPK1 are also modified
in vivo (18), these phosphorylated sites appear to be irrelevant to
in vivo functions (44). Inhibition of PfCDPK1 has been reported
to inhibit microneme secretion and invasion (17, 18). On the
other hand, TgCDPK3-deficient T. gondii does not exhibit major
defects in either motility or microneme secretion, suggesting that
TgCDPK3 substrates are likely different from those of PfCDPK1
in Plasmodium (22). Hence, successful complementation of
TgCDPK3 by PfCDPK1 in T. gondii is most likely due to the sim-
ilarity in protein structures and localization to the plasma mem-
brane.
Regardless of the specific targets within their respective parasites, we
show that transgenicT. gondii expressing P. falciparum proteins can
be used as a surrogate to screen for and to identify specific inhib-
itors of essential proteins from P. falciparum. Finding three drugs
(lestaurtinib, dasatinib, and PLX-4720) that affect PfCDPK1 ac-
tivity within T. gondii and also inhibit intraerythrocytic schizog-
ony of malaria parasites validates our transgenic T. gondii para-
sites as a system for the discovery of new antimalarials. Efforts to
discover novel specific inhibitors of Plasmodium proteins, includ-
ing PfDCPK1, are mostly based on in vitro screens using recom-
binant proteins. Inhibitors identified in this manner require fur-
ther testing to ensure cell permeability, bioavailability, and target
affinity within the parasite. Thus, PfCDPK1-expressing T. gondii
has the advantage of simultaneously screening for both specificity
and bioavailability in a cellular context. Moreover, screens that
rely on in vitro inhibition of recombinant proteins are unable to
identify prodrugs that are active against the target only after being
metabolized by the cell or drugs that inhibit function by disrupt-
ing protein-protein interactions. The limitations of screening for
inhibitors in an in vitro systemare underscored by the fact that two
small molecules, nilotinib and pazopanib, that were previously
shown to inhibit the kinase activity of recombinant PfCDPK1 did
FIG 6 Dose-response curves for kinase inhibitor effects on Plasmodium falcipa-
rum strain HB3 growth in red blood cells were determined. Parasites were
exposed to 2-fold dilutions of compounds for 48 h before 3H-labeled hypo-
xanthine was added to the assay plates. Plates were frozen after 20 h, and
[3H]hypoxanthine incorporation (cpm) was measured using a Trilux beta
counter. IC50s were calculated as the concentration at which [
3H]hypoxan-
thine incorporation was 50% of that in no-drug control wells with only the
DMSO vehicle. Reported values are the mean of 3 replicates. The y axis
represents inhibition of growth as a percent relative to the no-drug control.
The x axis represents the logarithm of the compound concentration in the
2-fold dilution series. Starting concentrations in the wells with the highest
dilutions were 10, 20, and 50 M for lestaurtinib, dasatinib, and PLX-4720,
respectively.
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not inhibit the ability of the kinase when it was expressed in T.
gondii.
The three drugs that we identified as having antiplasmodial
activity, namely, lestaurtinib, dasatinib, and PLX-4720, are either
already approved by the Food andDrug Administration (FDA) or
in late phases of clinical trials. Consequently, our results provide a
new set of drugs to be explored as potential antimalarials for hu-
mans. Dasatinib is a tyrosine kinase inhibitor and is FDA ap-
proved for use against chronic myeloid leukemia (CML), which is
caused by abnormal translocation of chromosomes, leading to
expression of unregulated kinase BCR-ABL (46). PLX-4720 is a
B-Raf kinase inhibitor, and its close analog vemurafenib (PLX-
4032) has been approved by the FDA for use against malignant
melanoma (47). The last of the inhibitors tested in P. falciparum,
lestaurtinib, is a staurosporine analog that is currently in phase II
clinical trials against acute myeloid leukemia (AML) caused by
mutant FMS-like tyrosine kinase receptor-3 (FLT3) (48).
One of the inhibitors found to affect PfCDPK1 function in T.
gondii, staurosporine, was shown previously to affect Plasmodium
invasion and development in red blood cells (39, 49). However,
the precise targets of staurosporine in these malaria parasites had
not been described previously. Our finding that staurosporine in-
hibits PfCDPK1 function within T. gondii at concentrations that
do not affect wild-type parasites suggests that PfCDPK1 might be
one of the major targets of this drug in Plasmodium. In this re-
spect, the effects of staurosporine on P. falciparum mentioned
above are consistent with the roles of PfCDPK1 in microneme
secretion, motility, invasion, and intracellular development (13,
17). As evident in our experiments using zaprinast, however, stau-
rosporine might target other kinases, including PKG.
Protein kinases, including CDPKs, phosphorylate their target
proteins by catalyzing the transfer of the -phosphate of the ATP
molecule to the hydroxyl group on serine, threonine, or tyrosine
residues of the substrate protein. Accordingly, these enzymes con-
tain a conserved ATP binding cleft, access to which is regulated by
a hydrophobic amino acid termed the gatekeeper residue. Many
small-molecule kinase inhibitors are competitive inhibitors that
mimic ATP binding and block ATP access to the cleft. Both dasat-
inib and PLX-4720 appear to inhibit PfCDPK1 function through
interactionswith theATPbinding region, since changing the gate-
keeper residue within this pocket to a larger amino acid renders
the protein resistant to the drugs within the context of T. gondii
iiEgress.While we do not knowwhat the functional consequences
of such a mutation in PfCDPK1 would be within the context of P.
falciparum, it is concerning that mutation of a single residue,
T145, makes PfCDPK1 unresponsive to inhibition, potentially
leading to resistant parasites. In this respect, lestaurtinib might be
amore promising inhibitor, as mutation of the gatekeeper residue
did not affect the sensitivity to the drug. While the PfCDPK1-
expressing strain was more sensitive to lestaurtinib than the
TgCDPK3-expressing strain, we did not find any strain that was
resistant to this inhibitor, raising the possibility that itmight target
proteins other than PfCDPK3.Nonetheless, the transgenicT. gon-
dii line expressing the PfCDPK1 gatekeeper mutant might be use-
ful as a counter-screening system, to identify small molecules that
inhibit PfCDPK1 independently of the gatekeeper residue or by
interacting with domains other than the ATP binding cleft. In
summary, the findings of this study illustrate that Tgcdpk3 mu-
tants of Toxoplasma can be exploited as an excellent surrogate
system for identifying new PfCDPK1 inhibitors, thus accelerating
the malaria drug discovery process, and in future can also be em-
ployed to study PfCDPK1 functions in cellular contexts.
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